Breaking news on cholesterol
Transporting Your Apolipoproteins Testing To The Next Level published
Fri, 09 May 2008 01:00:00 PDT
Randox produces high quality apolipoprotein tests for the diagnosis, monitoring and research of cardiovascular disease and related conditions. Apolipoproteins are essential components of lipoproteins, for example HDL and LDL, responsible for transporting cholesterol and triglycerides around the body. Six apolipoprotein tests are available from Randox: Apo A-I, Apo A-II, Apo B, Apo C-II, Apo C-III and Apo E.
LifeCycle Pharma Announces Positive Data From LCP-AtorFen Phase II Clinical Program published
Thu, 08 May 2008 01:00:00 PDT
LifeCycle Pharma A/S (OMX:LCP) announced positive results from the company's Phase II clinical program with LCP-AtorFen, a fixed-dose combination product of atorvastatin and fenofibrate for the treatment of mixed dyslipidemia. LCP-AtorFen is a convenient single tablet with a once-daily dosage profile and is without food effect. "The Phase II clinical program confirmed that LCP-AtorFen was safe and well-tolerated.
Sorting Of CEA Modulated By Cholesterol, Implications For Inflammatory Bowel Disease published
Sat, 03 May 2008 02:00:00 PDT
In polarized Caco-2 cells, cholesterol was depleted by a combination of synthesis inhibition and plasma membrane extraction with complexing agents. This led to an increased sorting of CEA to the basolateral surface. Interestingly, polarity was not significantly affected by this approach. The association of CEA to lipid rafts, cholesterol, and sphingolipid-enriched microdomains was inhibited in parallel.This study, performed by a team led by Dr.
Effects Of Rimonabant On Cardiometabolic Risk Profile Include Loss Of Visceral Fat And Mobilization Of Liver Fat published
Wed, 30 Apr 2008 01:00:00 PDT
At a late breaking presentation made on April 29th during the Annual meeting of the European Atherosclerosis Society held in Istanbul, the investigators of ADAGIO-LIPIDS presented the key findings of a one year trial aiming at further studying the effects of rimonabant on several features of HDL and on a comprehensive set of cardiometabolic markers.
Merck Receives Not Approvable Letter From FDA For MK-0524A (ER Niacin/laropiprant) published
Wed, 30 Apr 2008 01:00:00 PDT
Merck & Co., Inc. received a Not Approvable action letter from the U.S. Food and Drug Administration (FDA) for the Company's New Drug Application (NDA) for MK-0524A (ER niacin/laropiprant) for the treatment of primary hypercholesterolemia or mixed dyslipidemia. "We plan to meet with the FDA and to submit additional information to enable the agency to further evaluate the benefit/risk profile of MK-0524A," said Peter S. Kim, Ph. D.
Tredaptive Recommended For EU Approval For The Treatment Of Mixed Dyslipidaemia And Primary Hypercholesterolaemia published
Mon, 28 Apr 2008 01:00:00 PDT
Merck Sharp & Dohme Limited (MSD) announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for 'Tredaptive'™ (nicotinic acid/laropiprant, MSD) 1000 mg / 20 mg modified-release tablets for the treatment of mixed dyslipidaemia and primary hypercholesterolaemia.
Two Merck Medicines Recommended For Approval In The European Union published
Sun, 27 Apr 2008 00:00:00 PDT
Merck & Co., Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended two medicines for marketing approval in the European Union (EU). The CHMP recommended marketing approval for TREDAPTIVE™ (nicotinic acid/ laropiprant, MSD) 1000 mg/20 mg tablets for patients with dyslipidemia or primary hypercholesterolemia. Separately, the U.S.
FDA Provides Clarity To Isis Regarding The Development Path For Mipomersen published
Sat, 26 Apr 2008 00:00:00 PDT
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Genzyme Corp. (Nasdaq: GENZ) announced that the FDA has provided guidance regarding approval requirements for mipomersen. The FDA has indicated that reduction of LDL-cholesterol is an acceptable surrogate endpoint for accelerated approval of mipomersen for use in patients with homozygous familial hypercholesterolemia (hoFH).
CocoaVia Dark Chocolate Bars Shown To Lower Cholesterol published
Tue, 22 Apr 2008 05:00:00 PDT
The results of a University of Illinois study have demonstrated an effective way to lower cholesterol levels - by eating chocolate bars."Eating two CocoaVia dark chocolate bars a day not only lowered cholesterol, it had the unexpected effect of also lowering systolic blood pressure," said John Erdman, a U. of I. professor of food science and human nutrition.The study, funded in part by Mars Inc.
High Cholesterol In Your 40s Increases Risk Of Alzheimer's Disease published
Thu, 17 Apr 2008 00:00:00 PDT
People with high cholesterol in their early 40s are more likely to develop Alzheimer's disease than those with low cholesterol, according to research that will be presented at the upcoming American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12-19, 2008.
Lower Blood Pressure Linked To Statins published
Wed, 16 Apr 2008 00:00:00 PDT
An article published in the Archives of Internal Medicinereports that statins - medications that are usually prescribed to lowerblood cholesterol levels - may also lower blood pressure. Beatrice A.Golomb, M.D., Ph.D., (University of California, San Diego, La Jolla)and colleagues noted a modest but significant reduction in bloodpressure for patients taking statins.
Physicians And Patients Nationwide Discuss Controversial Results Of Recent Cholesterol Lowering Study published
Fri, 11 Apr 2008 03:00:00 PDT
Sermo (http://www.sermo.com), the largest physician-only online community, today announced the results of a physician survey prompted by the swirl of media coverage following the release of ENHANCE trial data at the recent American College of Cardiology (ACC) conference. The focus of the study was on the effectiveness of frequently prescribed cholesterol-lowering drugs, Vytorin and Zetia.
Cholesterol, Blood Pressure Control May Reverse Atherosclerosis In Adults With Diabetes published
Thu, 10 Apr 2008 02:00:00 PDT
Aggressively lowering cholesterol and blood pressure levels below current targets in adults with type 2 diabetes may help to prevent - and possibly reverse - hardening of the arteries, according to new research supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. Hardening of the arteries, also known as atherosclerosis, is the number one cause of heart disease and can lead to heart attack, stroke, and death.
eFoodSafety Launches Cinnechol(TM), An All-Natural Alternative To Conventional Cholesterol Drugs published
Wed, 09 Apr 2008 14:00:00 PDT
eFoodSafety.com (OTCBB: EFSF, http://www.efoodsafety.com), a researcher, developer, and marketer of whole food nutraceutical products, has launched an all-natural supplement, called Cinnechol™ (http://www.cinnechol.com), that offers a complementary and/or alternative solution to traditional cholesterol drugs.
Pieces Coming Together In Parkinson's, Cholesterol Puzzle published
Sat, 05 Apr 2008 00:00:00 PDT
In 2006, University of North Carolina at Chapel Hill researchers published a study that found people with low levels of LDL cholesterol are more likely to have Parkinson's disease than people with high LDL levels.But that study could not answer the question of whether low LDL (low-density lipoprotein) levels were present in study participants before they were diagnosed with Parkinson's, or if they developed low LDL levels after being diagnosed.
Levitra® Therapy Suitable For Men With High Cholesterol published
Sat, 05 Apr 2008 00:00:00 PDT
At the 23rd Annual European Association of Urology (EAU) Congress, results were presented which added evidence that Levitra® (vardenafil HCI) works very well in men with dyslipidemia.(1) The double-blind, placebo-controlled trial in about 400 men showed that Levitra® significantly improved the ability of men with erectile dysfunction (ED) and high cholesterol, to achieve and maintain an erection for successful sexual intercourse.(2) The trial, led by Dr.
Trans Fat: Why It's Time To Eliminate This Dietary Villain published
Fri, 04 Apr 2008 00:00:00 PDT
Trans fats are a cholesterol double whammy. Also known as trans fatty acids, trans fats raise low-density lipoprotein (LDL or "bad") cholesterol and lower high-density lipoprotein (HDL or "good") cholesterol.Experts consider trans fat the worst type of dietary fat. Trans fat contributes to heart disease by promoting low-grade inflammation in the blood vessels. And, trans fats are associated with a higher risk of developing type 2 diabetes.
Sen. Grassley Requests Information On Delay Of Results Of Study On Cholesterol Medication Vytorin published
Wed, 02 Apr 2008 07:00:00 PDT
Senate Finance Committee ranking member Chuck Grassley (R-Iowa) on Monday sent a letter to the CEOs of Merck and
Astrazeneca Stops Cholesterol Drug Trial Because Of Promising Results published
Tue, 01 Apr 2008 11:00:00 PDT
Pharmaceutical giant AstraZeneca announced yesterday, Monday 31st March, it was stopping the JUPITER clinical trial on its cholesterol-busting drug Crestor (rosuvastatin calcium) because early findings showed that the drug reduced deaths and risk of heart problems in patients compared to placebo.
Merck/Schering-Plough Pharmaceuticals Comments On Results Of The ENHANCE Study published
Mon, 31 Mar 2008 00:00:00 PDT
Results of ENHANCE (Ezetimibe aNd simvastatin in Hypercholesterolemia enhANces atherosClerosis rEgression), an imaging trial in 720 patients with heterozygous familial hypercholesterolemia (HeFH), a rare genetic condition that causes very high levels of LDL "bad" cholesterol and greatly increases
Phoenix Marketing Study Demonstrates Impact Of Press Coverage And Advertising On Cholesterol Drug Users And Medication Brands published
Fri, 28 Mar 2008 16:00:00 PDT
A burst of unfavorable or confusing publicity often prompts users of prescription medications to take swift actions that can hurt those medications' brand perception and market share, according to researchers at Phoenix Healthcare, a Phoenix Marketing International practice.
Karo Bio Strengthens Eprotirome Phase II Program With Additional Clinical Study published
Fri, 28 Mar 2008 10:00:00 PDT
Karo Bio initiates the second clinical phase IIb dose ranging study with eprotirome. This study will be conducted in dyslipidemia patients receiving concomitant treatment with the cholesterol absorption inhibitor ezetimibe. The first phase IIb study in 180 patients where eprotirome is given in addition to statin treatment is progressing according to plan. Karo Bio's compound eprotirome is a novel, selective, thyroid hormone agonist for treatment of dyslipidemia.
Daily Consumption Of CocoaVia Dark Chocolate Bars Significantly Lowered Cholesterol Levels And Systolic Blood Pressure In Study Participants published
Thu, 27 Mar 2008 05:00:00 PDT
Daily consumption of chocolate bars made with a patented combination of plant sterols and cocoa flavanols may affect cardiovascular risk by lowering elevated cholesterol levels and improving blood pressure, according to a new study published in the Journal of Nutrition.
VAP Test Helps Researchers Uncover Best Cholesterol Lowering Treatment For Type II Diabetes published
Wed, 26 Mar 2008 00:00:00 PDT
The VAP cholesterol test from Atherotech is helping physicians pinpoint the most effective cholesterol and heart disease risk lowering treatments in Type II diabetes patients, providing valuable and potentially lifesaving information to diabetics and the doctors who treat them.
Cholesterol-Associated Gene Variants Can Predict Cardiovascular Events published
Fri, 21 Mar 2008 05:00:00 PDT
A study appearing in this week's New England Journal of Medicine confirms that a combination of gene variants previously associated with cholesterol levels does reflect patients' cholesterol levels and can signify increased risk of heart attack, stroke or sudden cardiac death.
)
|
|
